Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Triple-mutant AML: too clever by HLF?

Vassiliou GS.

Blood. 2019 Jul 18;134(3):222-224. doi: 10.1182/blood.2019001533. No abstract available.

PMID:
31320364
2.

SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness.

Nguyen CH, Glüxam T, Schlerka A, Bauer K, Grandits AM, Hackl H, Dovey O, Zöchbauer-Müller S, Cooper JL, Vassiliou GS, Stoiber D, Wieser R, Heller G.

Sci Rep. 2019 Jun 24;9(1):9139. doi: 10.1038/s41598-019-45579-0.

3.

NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia.

Rudorf A, Müller TA, Klingeberg C, Kreutmair S, Poggio T, Gorantla SP, Rückert T, Schmitt-Graeff A, Gengenbacher A, Paschka P, Baldus C, Zeiser R, Vassiliou GS, Bradley A, Duyster J, Illert AL.

Blood. 2019 Jul 25;134(4):383-388. doi: 10.1182/blood.2018883140. Epub 2019 Jun 11.

4.

Genome-scale drop-out screens to identify cancer cell vulnerabilities in AML.

Basheer FT, Vassiliou GS.

Curr Opin Genet Dev. 2019 Feb;54:83-87. doi: 10.1016/j.gde.2019.04.004. Epub 2019 May 4. Review.

PMID:
31063922
5.

PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice.

Weber J, de la Rosa J, Grove CS, Schick M, Rad L, Baranov O, Strong A, Pfaus A, Friedrich MJ, Engleitner T, Lersch R, Öllinger R, Grau M, Menendez IG, Martella M, Kohlhofer U, Banerjee R, Turchaninova MA, Scherger A, Hoffman GJ, Hess J, Kuhn LB, Ammon T, Kim J, Schneider G, Unger K, Zimber-Strobl U, Heikenwälder M, Schmidt-Supprian M, Yang F, Saur D, Liu P, Steiger K, Chudakov DM, Lenz G, Quintanilla-Martinez L, Keller U, Vassiliou GS, Cadiñanos J, Bradley A, Rad R.

Nat Commun. 2019 Mar 29;10(1):1415. doi: 10.1038/s41467-019-09180-3.

6.

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.

Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS, Huntly BJP.

J Exp Med. 2019 Apr 1;216(4):966-981. doi: 10.1084/jem.20181276. Epub 2019 Mar 19.

7.

TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells.

Rasmussen KD, Berest I, Keβler S, Nishimura K, Simón-Carrasco L, Vassiliou GS, Pedersen MT, Christensen J, Zaugg JB, Helin K.

Genome Res. 2019 Apr;29(4):564-575. doi: 10.1101/gr.239277.118. Epub 2019 Feb 22.

PMID:
30796038
8.

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.

Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C, Bradley A, Jeremias I, Bates DO, Yusa K, Kouzarides T, Vassiliou GS.

Nat Commun. 2018 Dec 19;9(1):5378. doi: 10.1038/s41467-018-07620-0.

9.

Targeting MEK in vemurafenib-resistant hairy cell leukemia.

Caeser R, Collord G, Yao WQ, Chen Z, Vassiliou GS, Beer PA, Du MQ, Scott MA, Follows GA, Hodson DJ.

Leukemia. 2019 Feb;33(2):541-545. doi: 10.1038/s41375-018-0270-2. Epub 2018 Oct 19. No abstract available.

10.

An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.

Collord G, Tarpey P, Kurbatova N, Martincorena I, Moran S, Castro M, Nagy T, Bignell G, Maura F, Young MD, Berna J, Tubio JMC, McMurran CE, Young AMH, Sanders M, Noorani I, Price SJ, Watts C, Leipnitz E, Kirsch M, Schackert G, Pearson D, Devadass A, Ram Z, Collins VP, Allinson K, Jenkinson MD, Zakaria R, Syed K, Hanemann CO, Dunn J, McDermott MW, Kirollos RW, Vassiliou GS, Esteller M, Behjati S, Brazma A, Santarius T, McDermott U.

Sci Rep. 2018 Sep 10;8(1):13537. doi: 10.1038/s41598-018-31659-0.

11.

Combined Influence of B-Cell Receptor Rearrangement and Somatic Hypermutation on B-Cell Class-Switch Fate in Health and in Chronic Lymphocytic Leukemia.

Petrova VN, Muir L, McKay PF, Vassiliou GS, Smith KGC, Lyons PA, Russell CA, Anderson CA, Kellam P, Bashford-Rogers RJM.

Front Immunol. 2018 Aug 10;9:1784. doi: 10.3389/fimmu.2018.01784. eCollection 2018.

12.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, Stoilova B, Quivoron C, Heiblig M, Willekens C, Saada V, Alsafadi S, Vijayabaskar MS, Peniket A, Bernard OA, Agresta S, Yen K, MacBeth K, Stein E, Vassiliou GS, Levine R, De Botton S, Thakurta A, Penard-Lacronique V, Vyas P.

Nat Med. 2018 Aug;24(8):1167-1177. doi: 10.1038/s41591-018-0115-6. Epub 2018 Jul 16.

PMID:
30013198
13.

Prediction of acute myeloid leukaemia risk in healthy individuals.

Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, Barda N, Zuzarte PC, Heisler L, Sundaravadanam Y, Luben R, Hayat S, Wang TT, Zhao Z, Cirlan I, Pugh TJ, Soave D, Ng K, Latimer C, Hardy C, Raine K, Jones D, Hoult D, Britten A, McPherson JD, Johansson M, Mbabaali F, Eagles J, Miller JK, Pasternack D, Timms L, Krzyzanowski P, Awadalla P, Costa R, Segal E, Bratman SV, Beer P, Behjati S, Martincorena I, Wang JCY, Bowles KM, Quirós JR, Karakatsani A, La Vecchia C, Trichopoulou A, Salamanca-Fernández E, Huerta JM, Barricarte A, Travis RC, Tumino R, Masala G, Boeing H, Panico S, Kaaks R, Krämer A, Sieri S, Riboli E, Vineis P, Foll M, McKay J, Polidoro S, Sala N, Khaw KT, Vermeulen R, Campbell PJ, Papaemmanuil E, Minden MD, Tanay A, Balicer RD, Wareham NJ, Gerstung M, Dick JE, Brennan P, Vassiliou GS, Shlush LI.

Nature. 2018 Jul;559(7714):400-404. doi: 10.1038/s41586-018-0317-6. Epub 2018 Jul 9.

14.

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M, Knights AJ, Pardo M, Yu L, Choudhary JS, Metzakopian E, Iyer V, Yun H, Park N, Varela I, Bautista R, Collord G, Dovey O, Garyfallos DA, De Braekeleer E, Kondo S, Cooper J, Göttgens B, Bullinger L, Northcott PA, Adams D, Vassiliou GS, Huntly BJP.

Nat Genet. 2018 Jun;50(6):883-894. doi: 10.1038/s41588-018-0114-z. Epub 2018 May 7.

15.

Recurrent histone mutations in T-cell acute lymphoblastic leukaemia.

Collord G, Martincorena I, Young MD, Foroni L, Bolli N, Stratton MR, Vassiliou GS, Campbell PJ, Behjati S.

Br J Haematol. 2019 Feb;184(4):676-679. doi: 10.1111/bjh.15155. Epub 2018 Mar 30. No abstract available.

16.

JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics.

McKerrell T, Park N, Chi J, Collord G, Moreno T, Ponstingl H, Dias J, Gerasimou P, Melanthiou K, Prokopiou C, Antoniades M, Varela I, Costeas PA, Vassiliou GS.

Blood Adv. 2017 Jun 12;1(14):968-971. doi: 10.1182/bloodadvances.2017007047. eCollection 2017 Jun 13. No abstract available.

17.

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage.

Li J, Prins D, Park HJ, Grinfeld J, Gonzalez-Arias C, Loughran S, Dovey OM, Klampfl T, Bennett C, Hamilton TL, Pask DC, Sneade R, Williams M, Aungier J, Ghevaert C, Vassiliou GS, Kent DG, Green AR.

Blood. 2018 Feb 8;131(6):649-661. doi: 10.1182/blood-2017-09-806356. Epub 2017 Dec 27.

18.

Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control.

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millán-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N, De Braekeleer E, Ponstingl H, Hendrick A, Vakoc CR, Vassiliou GS, Kouzarides T.

Nature. 2017 Dec 7;552(7683):126-131. doi: 10.1038/nature24678. Epub 2017 Nov 27.

19.

Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.

Dovey OM, Cooper JL, Mupo A, Grove CS, Lynn C, Conte N, Andrews RM, Pacharne S, Tzelepis K, Vijayabaskar MS, Green P, Rad R, Arends M, Wright P, Yusa K, Bradley A, Varela I, Vassiliou GS.

Blood. 2017 Oct 26;130(17):1911-1922. doi: 10.1182/blood-2017-01-760595. Epub 2017 Aug 23.

20.

Therapeutics: Click and discover.

Vassiliou GS, Balasubramanian S.

Nature. 2017 Aug 9;548(7666):162-164. doi: 10.1038/548162a. No abstract available.

PMID:
28796205
21.

Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.

Taylor SJ, Duyvestyn JM, Dagger SA, Dishington EJ, Rinaldi CA, Dovey OM, Vassiliou GS, Grove CS, Langdon WY.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaam8060. doi: 10.1126/scitranslmed.aam8060.

PMID:
28794285
22.

Enhancing the genome editing toolbox: genome wide CRISPR arrayed libraries.

Metzakopian E, Strong A, Iyer V, Hodgkins A, Tzelepis K, Antunes L, Friedrich MJ, Kang Q, Davidson T, Lamberth J, Hoffmann C, Davis GD, Vassiliou GS, Skarnes WC, Bradley A.

Sci Rep. 2017 May 22;7(1):2244. doi: 10.1038/s41598-017-01766-5.

23.

Clonal haematopoiesis is not prevalent in survivors of childhood cancer.

Collord G, Park N, Podestà M, Dagnino M, Cilloni D, Jones D, Varela I, Frassoni F, Vassiliou GS.

Br J Haematol. 2018 May;181(4):537-539. doi: 10.1111/bjh.14630. Epub 2017 Apr 3. No abstract available.

24.

A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes.

de la Rosa J, Weber J, Friedrich MJ, Li Y, Rad L, Ponstingl H, Liang Q, de Quirós SB, Noorani I, Metzakopian E, Strong A, Li MA, Astudillo A, Fernández-García MT, Fernández-García MS, Hoffman GJ, Fuente R, Vassiliou GS, Rad R, López-Otín C, Bradley A, Cadiñanos J.

Nat Genet. 2017 May;49(5):730-741. doi: 10.1038/ng.3817. Epub 2017 Mar 20.

25.

Genome-wide transposon screening and quantitative insertion site sequencing for cancer gene discovery in mice.

Friedrich MJ, Rad L, Bronner IF, Strong A, Wang W, Weber J, Mayho M, Ponstingl H, Engleitner T, Grove C, Pfaus A, Saur D, Cadiñanos J, Quail MA, Vassiliou GS, Liu P, Bradley A, Rad R.

Nat Protoc. 2017 Feb;12(2):289-309. doi: 10.1038/nprot.2016.164. Epub 2017 Jan 12.

PMID:
28079877
26.

Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones.

Bashford-Rogers RJ, Palser AL, Hodkinson C, Baxter J, Follows GA, Vassiliou GS, Kellam P.

Exp Hematol. 2017 Feb;46:31-37.e10. doi: 10.1016/j.exphem.2016.09.010. Epub 2016 Sep 28.

27.

Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.

Mupo A, Seiler M, Sathiaseelan V, Pance A, Yang Y, Agrawal AA, Iorio F, Bautista R, Pacharne S, Tzelepis K, Manes N, Wright P, Papaemmanuil E, Kent DG, Campbell PC, Buonamici S, Bolli N, Vassiliou GS.

Leukemia. 2017 Mar;31(3):720-727. doi: 10.1038/leu.2016.251. Epub 2016 Sep 8.

28.

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS, Yusa K.

Cell Rep. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079.

29.

JAK2 V617F clonal disorders: fate or chance?

Vassiliou GS.

Blood. 2016 Aug 25;128(8):1032-3. doi: 10.1182/blood-2016-07-726448. No abstract available.

30.

Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.

Kühn MW, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, Cusan M, Farnoud N, Mupo A, Grove C, Koche R, Bradner JE, de Stanchina E, Vassiliou GS, Hoshii T, Armstrong SA.

Cancer Discov. 2016 Oct;6(10):1166-1181. Epub 2016 Aug 17.

31.

Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse.

Bashford-Rogers RJ, Nicolaou KA, Bartram J, Goulden NJ, Loizou L, Koumas L, Chi J, Hubank M, Kellam P, Costeas PA, Vassiliou GS.

Leukemia. 2016 Dec;30(12):2312-2321. doi: 10.1038/leu.2016.142. Epub 2016 May 23.

32.

Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice.

Dovey OM, Chen B, Mupo A, Friedrich M, Grove CS, Cooper JL, Lee B, Varela I, Huang Y, Vassiliou GS.

Haematologica. 2016 Aug;101(8):e328-31. doi: 10.3324/haematol.2016.146159. Epub 2016 May 12. No abstract available.

33.

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodkinson C, Baxter J, Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R, Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Mustonen V, Vassiliou GS.

Blood. 2016 Jul 7;128(1):e1-9. doi: 10.1182/blood-2015-11-683334. Epub 2016 Apr 27.

34.

Rapid parallel acquisition of somatic mutations after NPM1 in acute myeloid leukaemia evolution.

Grove CS, Bolli N, Manes N, Varela I, Van't Veer M, Bench A, Eldaly H, Wedge D, Van Loo P, Vassiliou GS.

Br J Haematol. 2017 Mar;176(5):825-829. doi: 10.1111/bjh.13999. Epub 2016 Apr 7. No abstract available.

PMID:
27062498
35.

Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice.

Maresch R, Mueller S, Veltkamp C, Öllinger R, Friedrich M, Heid I, Steiger K, Weber J, Engleitner T, Barenboim M, Klein S, Louzada S, Banerjee R, Strong A, Stauber T, Gross N, Geumann U, Lange S, Ringelhan M, Varela I, Unger K, Yang F, Schmid RM, Vassiliou GS, Braren R, Schneider G, Heikenwalder M, Bradley A, Saur D, Rad R.

Nat Commun. 2016 Feb 26;7:10770. doi: 10.1038/ncomms10770.

36.

CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.

Weber J, Öllinger R, Friedrich M, Ehmer U, Barenboim M, Steiger K, Heid I, Mueller S, Maresch R, Engleitner T, Gross N, Geumann U, Fu B, Segler A, Yuan D, Lange S, Strong A, de la Rosa J, Esposito I, Liu P, Cadiñanos J, Vassiliou GS, Schmid RM, Schneider G, Unger K, Yang F, Braren R, Heikenwälder M, Varela I, Saur D, Bradley A, Rad R.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13982-7. doi: 10.1073/pnas.1512392112. Epub 2015 Oct 27.

37.

Aging as a driver of leukemogenesis.

McKerrell T, Vassiliou GS.

Sci Transl Med. 2015 Sep 23;7(306):306fs38. doi: 10.1126/scitranslmed.aac4428. Epub 2015 Sep 23. No abstract available.

38.

A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.

Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ, Huntly BJ.

J Exp Med. 2015 Sep 21;212(10):1551-69. doi: 10.1084/jem.20141661. Epub 2015 Aug 24.

39.

Gene expression changes in HLA mismatched mixed lymphocyte cultures reveal genes associated with allorecognition.

Nicolaidou V, Stylianou C, Koumas L, Vassiliou GS, Bodman-Smith KB, Costeas P.

Tissue Antigens. 2015 Apr;85(4):267-77. doi: 10.1111/tan.12543.

40.

Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis.

McKerrell T, Park N, Moreno T, Grove CS, Ponstingl H, Stephens J; Understanding Society Scientific Group, Crawley C, Craig J, Scott MA, Hodkinson C, Baxter J, Rad R, Forsyth DR, Quail MA, Zeggini E, Ouwehand W, Varela I, Vassiliou GS.

Cell Rep. 2015 Mar 3;10(8):1239-45. doi: 10.1016/j.celrep.2015.02.005. Epub 2015 Feb 26.

41.

Effect of mutation order on myeloproliferative neoplasms.

Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, Döhner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR.

N Engl J Med. 2015 Feb 12;372(7):601-612. doi: 10.1056/NEJMoa1412098.

42.

Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol.

Bolli N, Manes N, McKerrell T, Chi J, Park N, Gundem G, Quail MA, Sathiaseelan V, Herman B, Crawley C, Craig JI, Conte N, Grove C, Papaemmanuil E, Campbell PJ, Varela I, Costeas P, Vassiliou GS.

Haematologica. 2015 Feb;100(2):214-22. doi: 10.3324/haematol.2014.113381. Epub 2014 Nov 7.

43.

Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.

Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, Davies HR, Papaemmanuil E, Gundem G, Shlien A, Bolli N, Behjati S, Tarpey PS, Nangalia J, Massie CE, Butler AP, Teague JW, Vassiliou GS, Green AR, Du MQ, Unnikrishnan A, Pimanda JE, Teh BT, Munshi N, Greaves M, Vyas P, El-Naggar AK, Santarius T, Collins VP, Grundy R, Taylor JA, Hayes DN, Malkin D; ICGC Breast Cancer Group; ICGC Chronic Myeloid Disorders Group; ICGC Prostate Cancer Group, Foster CS, Warren AY, Whitaker HC, Brewer D, Eeles R, Cooper C, Neal D, Visakorpi T, Isaacs WB, Bova GS, Flanagan AM, Futreal PA, Lynch AG, Chinnery PF, McDermott U, Stratton MR, Campbell PJ.

Elife. 2014 Oct 1;3. doi: 10.7554/eLife.02935.

44.

Capturing needles in haystacks: a comparison of B-cell receptor sequencing methods.

Bashford-Rogers RJ, Palser AL, Idris SF, Carter L, Epstein M, Callard RE, Douek DC, Vassiliou GS, Follows GA, Hubank M, Kellam P.

BMC Immunol. 2014 Aug 5;15:29. doi: 10.1186/s12865-014-0029-0.

45.

Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?

Grove CS, Vassiliou GS.

Dis Model Mech. 2014 Aug;7(8):941-51. doi: 10.1242/dmm.015974. Review.

46.

Vitamin B₁₂-dependent taurine synthesis regulates growth and bone mass.

Roman-Garcia P, Quiros-Gonzalez I, Mottram L, Lieben L, Sharan K, Wangwiwatsin A, Tubio J, Lewis K, Wilkinson D, Santhanam B, Sarper N, Clare S, Vassiliou GS, Velagapudi VR, Dougan G, Yadav VK.

J Clin Invest. 2014 Jul;124(7):2988-3002. doi: 10.1172/JCI72606. Epub 2014 Jun 9.

47.

Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis.

Chi J, Nicolaou KA, Nicolaidou V, Koumas L, Mitsidou A, Pierides C, Manoloukos M, Barbouti K, Melanthiou F, Prokopiou C, Vassiliou GS, Costeas P.

Leukemia. 2014 May;28(5):1152-4. doi: 10.1038/leu.2013.382. Epub 2013 Dec 24. No abstract available.

48.

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.

Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S, Cannizzaro E, Osaki H, Wiese M, Putwain S, Fong CY, Grove C, Craig J, Dittmann A, Lugo D, Jeffrey P, Drewes G, Lee K, Bullinger L, Prinjha RK, Kouzarides T, Vassiliou GS, Huntly BJ.

Leukemia. 2014 Feb;28(2):311-20. doi: 10.1038/leu.2013.338. Epub 2013 Nov 13.

49.

Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations.

Bashford-Rogers RJ, Palser AL, Huntly BJ, Rance R, Vassiliou GS, Follows GA, Kellam P.

Genome Res. 2013 Nov;23(11):1874-84. doi: 10.1101/gr.154815.113. Epub 2013 Jun 6.

50.

Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture.

Conte N, Varela I, Grove C, Manes N, Yusa K, Moreno T, Segonds-Pichon A, Bench A, Gudgin E, Herman B, Bolli N, Ellis P, Haddad D, Costeas P, Rad R, Scott M, Huntly B, Bradley A, Vassiliou GS.

Leukemia. 2013 Sep;27(9):1820-5. doi: 10.1038/leu.2013.117. Epub 2013 Apr 18.

Supplemental Content

Loading ...
Support Center